This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Green MR (2004) Targeting targeted therapy. N Engl J Med 350: 2191–2193
Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139
Paez JG et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500
Shigematsu H et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339–346
Thatcher N et al. (2005) Results of a Phase III placebo-controlled study (ISEL) of gefitinib (IRESSA) plus best supportive care (BSC) in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens [abstract #LB-6]. ISEL Investigators. AACR 96th Annual Meeting
Acknowledgements
The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Amir Onn received honoraria from AstraZeneca. Roy S Herbst is a consultant and has received research funds from AstraZeneca.
Rights and permissions
About this article
Cite this article
Onn, A., Herbst, R. What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?. Nat Rev Clin Oncol 2, 290–291 (2005). https://doi.org/10.1038/ncponc0191
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0191